- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: CCL18.
Displaying page 1 of 1.
| EudraCT Number: 2006-002174-22 | Sponsor Protocol Number: Avifibro | Start Date*: 2006-11-08 |
| Sponsor Name:Mondobiotech Laboratories Anstalt | ||
| Full Title: Influence of inhaled Aviptadil on CCL18 serum concentrations in patients with pulmonary fibrosis | ||
| Medical condition: Pulmonary Fibrosis categorized as UIP or NSIP | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-001561-32 | Sponsor Protocol Number: 201900237 | Start Date*: 2020-04-28 | ||||||||||||||||
| Sponsor Name:University Medical Center Groningen | ||||||||||||||||||
| Full Title: Dupilumab in adults with severe chronic hand eczema with an inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled proof of concept efficacy study | ||||||||||||||||||
| Medical condition: Hand eczema | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: NL (Ongoing) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2019-004998-34 | Sponsor Protocol Number: B-2660-203 | Start Date*: 2020-07-16 | |||||||||||
| Sponsor Name:Blade Therapeutics, Inc. | |||||||||||||
| Full Title: A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacodynamics, Pharmacokinetics, and Safety of BLD-2660 Administered Orally in Subjects with Idiopathic Pulmonary Fibrosis | |||||||||||||
| Medical condition: Idiopathic Pulmonary Fibrosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-002258-60 | Sponsor Protocol Number: UMCN-ONCO-201302 | Start Date*: 2013-08-30 | |||||||||||
| Sponsor Name:Radboud University Nijmegen Medical Centre | |||||||||||||
| Full Title: prediction of everolimus-induced interstitial lung disease in breast cancer patients; maximizing efficacy by reducing toxicity | |||||||||||||
| Medical condition: breast cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: NL (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-004278-41 | Sponsor Protocol Number: 01081 | Start Date*: 2010-04-19 |
| Sponsor Name:Institut Jules Bordet | ||
| Full Title: A phase II study of doxorubicin, cyclophosphamide and vindesine with valproic acid in patients with refractory or relapsing small cell lung cancer after platinum derivatives and etoposide. | ||
| Medical condition: This is a prospective phase II study investigating well-known chemotherapeutic (doxorubicin, cyclophosphamide, vindesine) and antiepileptic (valproate) agents, in combination, for the treatment of... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2007-007267-25 | Sponsor Protocol Number: C07-38 | Start Date*: 2008-06-02 | |||||||||||
| Sponsor Name:INSERM | |||||||||||||
| Full Title: Immunothérapie par vaccination anti-rougeoleuse chez l'adulte atteint de dermatite atopique | |||||||||||||
| Medical condition: Adultes (hommes, femmes) porteurs de Dermatite Atopique (DA) modérée à sévère (SCORAD supérieur ou égal à 15). | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-015811-42 | Sponsor Protocol Number: GZGD03109 | Start Date*: 2010-12-20 | |||||||||||
| Sponsor Name:Genzyme Europe B.V. | |||||||||||||
| Full Title: A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once Daily versus Twice Daily Dosing of Genz-112638 in Patients wit... | |||||||||||||
| Medical condition: Gaucher Disease Type I | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) PT (Completed) AT (Completed) GR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-000498-42 | Sponsor Protocol Number: PB-06-001 | Start Date*: 2008-05-08 | |||||||||||
| Sponsor Name:Protalix Biotherapeutics | |||||||||||||
| Full Title: A Phase III Multicenter, Randomized, Double-Blind Trial to Assess the Safety and Efficacy of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patient... | |||||||||||||
| Medical condition: Gaucher disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) ES (Completed) IT (Completed) Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-002840-21 | Sponsor Protocol Number: HGT-GCB-039 | Start Date*: 2007-10-30 | |||||||||||
| Sponsor Name:Shire Human Genetic Therapies Inc | |||||||||||||
| Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Group Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy Compared with Imiglucerase in Patients with Type I Gauc... | |||||||||||||
| Medical condition: Type I Gaucher disease Enfermedad de Gaucher tipo 1 | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) GB (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-024332-42 | Sponsor Protocol Number: BAY63-2521/13605 | Start Date*: 2014-04-10 | |||||||||||
| Sponsor Name:Bayer HealthCare AG | |||||||||||||
| Full Title: A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmon... | |||||||||||||
| Medical condition: pulmonary hypertension associated with idiopathic interstitial pneumonias | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) DE (Completed) ES (Completed) BE (Completed) GB (Completed) PT (Completed) DK (Completed) GR (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.